Skip to main content

Emerging treatment modalities for systemic therapy in hepatocellular carcinoma


Hepatocellular carcinoma (HCC) has long been a major global clinical problem as one of the most common malignant tumours with a high rate of recurrence and mortality. Although potentially curative therapies are available for the early and intermediate stages, the treatment of patients with advanced HCC remains to be resolved. Fortunately, the past few years have shown the emergence of successful systemic therapies to treat HCC. At the molecular level, HCC is a heterogeneous disease, and current research on the molecular characteristics of HCC has revealed numerous therapeutic targets. Targeted agents based on signalling molecules have been successfully supported in clinical trials, and molecular targeted therapy has already become a milestone for disease management in patients with HCC. Immunotherapy, a viable approach for the treatment of HCC, recognizes the antigens expressed by the tumour and treats the tumour using the immune system of the host, making it both selective and specific. In addition, the pipeline for HCC is evolving towards combination therapies with promising clinical outcomes. More drugs designed to focus on specific pathways and immune checkpoints are being developed in the clinic. It has been demonstrated that some drugs can improve the prognosis of patients with HCC in first- or second-line settings, and these drugs have been approved by the Food and Drug Administration or are nearing approval. This review describes targeting pathways and systemic treatment strategies in HCC and summarizes effective targeted and immune-based drugs for patients with HCC and the problems encountered.


Liver cancer is the fourth most common cause of cancer deaths worldwide [1]. Hepatocellular carcinoma (HCC) is a prominent and complex subtype of primary liver cancer, accounting for over 90% of cases [2]. Hepatectomy, liver transplantation, and ablation are potentially curative for patients diagnosed with early-stage HCC [3, 4]; however, conventional systemic chemotherapy loses its survival benefits for advanced patients [5]. It is absolutely essential to develop unique treatment modalities to better manage HCC.

Recently, there has been significant progress in the understanding of signalling pathways, techniques to detect tumour progression, and drugs to block pathway activity, providing opportunities to develop precise treatments [6]. Multiple aberrant pathways in HCC have been characterized such as the Ras-Raf-MAPK, PI3K-AKT-mTOR, Wnt-β-catenin, and JAK-STAT pathways [7,8,9,10]. Drugs targeting these pathways have demonstrated encouraging survival benefits and bring considerable hope to patients with HCC [11]. Furthermore, immunotherapy has been suggested as a neopotential treatment for HCC patients [12]. Immune checkpoint inhibitors (ICIs) have been used successfully in patients with HCC [13]. These targeted and immune-based agents, including sorafenib, lenvatinib, regorafenib, and nivolumab are already available as clinical options for first-line or second-line treatment [14,15,16].

With the development of molecular medicine, systemic therapy significantly enhances quality of life and has become a major means of treatment for HCC, particularly for combination therapy and subsequent therapy [17, 18]. However, targeted therapies are often correlated with considerable resistance and adverse events (AEs), presenting a substantial challenge to further broadening existing treatment approaches for patients with HCC [19].

This review describes important pathways in HCC and discusses recent developments in targeted therapy for these tumours, including the evolution of therapeutic modalities and available options, with the goal of specifying precise treatment protocols for HCC in future studies.

Targeting pathways in HCC

Hepatocarcinogenesis is a multielement and multistep process and is associated with aberrant activation of diverse signalling pathways (Fig. 1) involving both receptor and nonreceptor actions of tyrosine kinase proteins [20]. The exploration of tumour signal transduction has been an active area in the field of basic tumour research and is the theoretical basis for various molecular targeted drugs.

Fig. 1
figure 1

Signaling pathways and therapeutic targets in focus for HCC

Ras-Raf-MAPK pathway

The Ras-Raf-MAPK pathway is a classic cellular signalling pathway that is generally associated with cell growth and proliferation and is located downstream of several tyrosine kinase receptors [21]. In HCC, the overexpression of several molecules in this pathway such as ras, raf-1, and ERK has been previously reported [22,23,24]. These variations often indicate a poor prognosis and short survival time in patients [25]. In addition, increased expression of the MAPK pathway is found in high-grade tumours [26]. Therefore, MAPK pathways may play a central role in liver carcinogenesis. This conclusion has been confirmed in preclinical trials, where specific MEK inhibitors blocked tumour angiogenesis and induced apoptosis by inhibiting this pathway [27]. Targeted drugs for precise molecules in this pathway have also shown promising antitumour activity in clinical trials [28, 29]. Additionally, the HBV X protein and HCV core protein can also activate the Ras-Raf-MAPK pathway [30, 31], and these studies indicate that this pathway may play a potential role in the progression of hepatitis to HCC.

PI3K-AKT-mTOR pathways

The PI3K-AKT-mTOR pathway plays a vital role in regulating leading cellular processes such as cell survival and metabolism, and thus its deregulation is associated with malignant transformation and recurrence, including in liver cancer [32]. The analysis of tumour tissues from HCC patients revealed that mTOR signalling activity was observed in almost 50% of HCC samples [33]. This unrestricted activity is associated with abnormal PTEN as a tumour suppressor [34]. Notably, mutations in the PI3K-AKT-mTOR pathway are uncommon in HCC, and activation of this pathway is often largely due to ligand-dependent receptor activation [35]. When compared with normal samples, tumours containing aberrant levels of pathway components such as p-AKT, RICTOR, and pRPS6 are usually of a higher grade and have a worse overall prognosis [36, 37]. Moreover, cholangiocarcinoma, the second most prevalent primary liver cancer, also shows an upregulation of this pathway [38]. Some studies have demonstrated that a further increase in mTOR activation was identified in advanced HCC and in larger tumours [39]. Aberrant mTOR activation involves the PI3K-AKT and MAPK-ERK signalling pathways, which are often coinduced in HCC [40]. It has been reported that the blockade of both pathways boosts the response of HCC cells to sorafenib [41]. In addition, the PI3K-AKT-mTOR pathway is the cornerstone of the runaway signalling network in HCC and is a predominant driver in sorafenib resistance [42]. mTOR inhibitors are beneficial for active HCC patients after liver transplantation [43]. Various drugs targeting this pathway have shown excellent antitumour effects, particularly in combination with MAPK pathway inhibitors.

Wnt-β-catenin pathways

Activation of the Wnt-β-catenin pathway in HCC is strongly related to early development, poorly differentiated tumours, earlier recurrence, and an adverse prognosis of HCC [44, 45]. Wnt functions as a regulator in liver regeneration and the self-renewal of progenitor and pluripotent stem cells and may be an optimal target for precise therapy [46]. Forty percent of HCC patients exhibit altered Wnt-β-catenin signalling, and nearly 20% of these mutations are caused by the β-catenin gene itself [47, 48]. The tissue analysis of HCC samples has demonstrated that the activation of β-catenin participates in abnormal cellular proliferation, tumour metastasis, and vascular invasion [49]. Hepatitis B and C virus infections induce overexpression of β-catenin, thus promoting hepatocarcinogenesis [50, 51].

JAK-STAT pathways

In both normal and tumour cells, the JAK-STAT pathway serves multiple essential biological functions. Abnormalities of JAK-STAT can be found in over 45% of liver cancers [52]. In HCC, aberrantly activated JAK-STAT signalling results in the malfunction of downstream target genes, thereby controlling survival, cell division, angiogenesis, and metastasis [53]. The activation of STATs in tumours is considerably higher than that in adjacent liver tissues, and this degree of activation is responsible for the poor prognosis of tumour patients [54]. The JAK-STAT pathway is also responsible for the preservation of cancer stem cells with tumour propagation capacity in HCC and the establishment of an immunosuppressive microenvironment [55]. Given the oncogenic activity of JAK-STAT activation, particularly in the absence of a STAT3 disorder, targeting this pathway appears to be a favourable strategy for treating HCC.

Hippo-YAP pathways

The Hippo-YAP pathway has critical roles in controlling organ size and tissue homeostasis. However, deregulation of Hippo-YAP signalling has been demonstrated in multiple cancers and leads to various oncogenic effects [56]. Signalling is activated not only through the interaction between appropriate extracellular ligands and their cellular receptors but also via cell polarity and adhesion [57]. The expression levels of the YAP protein and mRNA were very different in normal and cancerous liver tissues, and excessive activation of YAP in mice led to hepatocellular carcinogenesis [58]. Elevated YAP levels are an early event in the development of HCC and are largely attributed to gene amplification and posttranscriptional regulation [59]. Notably, nearly 50% of HCC patients display altered YAP overexpression and nuclear localization [60], and detection of the components of Hippo-YAP signalling may provide prognostic value for patients with HCC, as the amount of nuclear YAP is highly correlated with the survival time of patients [61].

Proangiogenic pathways

HCC is a highly vascularized tumour, and angiogenesis is responsible for its tumorigenesis. Proangiogenic factors such as VEGF, FGF, PDGF, and hepatocyte growth factor trigger endothelial cell tyrosine kinases and downstream intracellular signalling via Ras-Raf-mTOR-Wnt pathways to activate angiogenesis [62]. These factors are expressed on endothelial cells and stimulate tumour neoangiogenesis, invasion, and migration. VEGF receptor expression is upregulated in HCC specimens, and elevated levels are negatively correlated with the overall survival (OS) of patients [63]. FGF is overexpressed in HCC compared with normal tissues, and this variation is recognized as oncogenic activity [64]. Dysregulation of PDGF resulting in tumorigenesis has been identified in several tumours, including HCC, and PDGF expression is markedly increased in highly metastatic cancer [65]. EGFR and IGFR are similar tyrosinase receptors, except that they have less impact on angiogenesis.

Treatment advances in systemic therapy

The occurrence of HCC is related to the complex interaction between signal transduction pathways, the tumour microenvironment, and the genetic background, which leads to many opportunities for precise treatment. The treatment regimens for HCC have undergone a major transformation with the investigation of the molecular mechanism, and many new treatment approaches have become available as therapeutic options (Fig. 2). Tyrosine kinase inhibitors (TKIs) and ICIs have improved the quality of life and greatly extended the survival time of patients with HCC. Table 1 provides a list of clinical trials evaluating systemic therapeutic agents in HCC.

Fig. 2
figure 2

Systemic treatment strategies in HCC

Table 1 Clinical trials of systemic therapy in HCC

Targeted therapy

Within the multitude of molecules known to be growth promoters, members of the family of protein tyrosine kinases have a central role in regulating tumour-initiating activity [66], and this is the main object of targeted therapy.

Since the availability of sorafenib as an antiangiogenic and antiproliferative agent in 2007, TKIs have revolutionized the management of HCC, ushering in the epoch of systemic therapies. Sorafenib prolonged the median overall survival (mOS) of patients with advanced HCC from 8 to 11 months with a tolerated toxicity profile [67]. In a subsequent trial, this endpoint was further extended to 14.7 months [68]. However, no additional valid systemic treatment alternatives have been identified for nearly a decade after the introduction of sorafenib. In recent years, several novel treatment compounds have demonstrated benefits as first- and second-line regimens. New eligible agents, such as lenvatinib in the first-line setting and regorafenib, cabozantinib, and ramucirumab in the second-line setting, have already been demonstrated to improve clinical outcomes, although the mOS remains at approximately one year [69, 70]. With all of these drugs, the study design was similar to that of sorafenib, which typically selected patients with advanced HCC in stage B or C BCLC and assessed OS as the primary endpoint (Table 1) [14, 71]. To date, TKIs are effective treatments that have received widespread support for the treatment of advanced HCC worldwide.

Interestingly, the drugs showing significant clinical effects are almost all multikinase inhibitors (MKIs), which may be attributed to the multiple activation mechanism of hepatocellular carcinogenesis [72]. If patients with advanced HCC have failed locoregional treatment or cannot receive a liver transplant, MKIs are considered acceptable treatment agents. Certainly, if the goal is a driver mutation, the role of a single-target inhibitor may be primarily beneficial [73], but several single-target TKIs have been tested in HCC without positive results, including erlotinib, refametinib, and selumetinib [74,75,76].

Nevertheless, targeted therapies are correlated with AEs, modest efficacy, and regular occurrence of drug resistance. Fortunately, breakthroughs in immunotherapy have brought fresh hope to HCC patients.


The object of immunotherapy is the immune system and tumour microenvironment of patients, rather than directly killing or interfering with tumour cells [77]. Common immune checkpoints in the tumour are PD-1/PD-L1 and CTLA-4. The association between PD-1 and HCC was first seen in patients with HBV infection, where higher PD-1 expression was associated with an increased viral load and a fold-increased risk of HCC [78]. There are various monoclonal antibodies approved by the FDA for use in the clinic: nivolumab, pembrolizumab, and camrelizumab for anti-PD-1 and atezolizumab, aveluma, and durvalumab for anti-PD-L1 [79]. Nivolumab is the first ICI approved as a second-line therapy by the FDA to treat advanced HCC based on results from the CheckMate-040 trial [80]. Subsequently, pembrolizumab and camrelizumab also received regulatory approval in advanced HCC patients treated with sorafenib [81, 82]. Accordingly, nivolumab and pembrolizumab may be particularly beneficial for patients who are not suitable for TKIs [83]. Although CTLA-4 inhibitors have been available for solid tumours, they have not been adequately demonstrated to improve survival for treating this malignancy [84]. Common anti-CTLA-4 antibodies such as ipilimumab and tremelimumab are currently used in combination with anti-PD/anti-PD-L1 in the treatment of liver cancer. Nevertheless, immunotherapy is only approved for a limited number of cancer patients for various reasons, and it is necessary to explore additional immune checkpoints beyond PD-1/PD-L1.

In some tumour patients, ICIs do not elicit tumour-specific T-cell activity and are less effective in treating patients. However, this effect can be improved by cell therapy [85]. Cell therapy, such as CAR-T, TCR-T or CAR-NK, is an emerging field of treating malignant tumours. Several cell therapies for HCC have already successfully entered clinical trials and have presented excellent experimental results [86,87,88,89]. Therefore, cell therapies can significantly prevent the recurrence of HCC and represent a powerful treatment approach for HCC.

With the improvement of immunotherapy and the positive effects of immunotherapeutic drugs in the treatment of HCC, interest in adjuvant immunotherapy after HCC resection has increased. Immunologic drugs such as 131I-metuximab significantly improved the survival outcomes of patients after hepatectomy [90]. The rate of pathologic complete response was 29% in a phase II study evaluating nivolumab with or without ipilimumab in patients with resectable HCC [91]. This encouraging result has yet to be confirmed in the ongoing phase III trial. Neoadjuvant immunotherapy with nivolumab plus ipilimumab has demonstrated antitumour activity in an early phase trial [92]. Cytokine-induced killer (CIK) cell immunotherapy for early HCC brings a median RFS benefit of 14 months but lacks survival advantages in advanced HCC patients as an adjuvant therapy, but this result can also be enhanced by targeting myeloid-derived suppressor cells [93, 94]. A similar encouraging adjuvant immunotherapy is HSP70 mRNA-transfected dendritic cell therapy [86].

Clinical trials involving more ICIs for HCC are under investigation, including trials targeting transforming growth factor-β (TGF-β), T cell immunoglobulin and mucin-containing protein 3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), T cell Ig and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) and lymphocyte activation gene-3 (LAG-3).

Epigenetic therapy

Sequential epigenetic alterations in regulatory genes can lead to oncogene activation and inactivation or the loss of oncogenes, resulting in tumorigenesis [95]. Major elements of epigenetic mechanisms such as ncRNAs, DNA methylation, and histone modifications change their expression or function in the background of liver fibrosis, cirrhosis, and HCC [96]. Epigenetic dysregulation represents an important function in the aetiology of HCC, which has recently been widely recognized [97]. Generally, epigenetic alterations are largely intrinsically reversible and can be seen as therapeutic targets to block the progression of HCC. Numerous drugs that specifically target epigenetic modifiers have been developed and proven successful against multiple tumour models, and several of these are in clinical trials [98, 99].

Combination therapy

Anti-angiogenic agents in combination with checkpoint inhibitors

For patients with solid tumours, vascular abnormalities can enable the tumour to evade surveillance and attack by the immune system, and these abnormalities arise from elevated angiogenic factors such as VGEF and angiopoietin 2 (ANG2). Agents targeting these molecules can normalize tumour vasculature, which in turn enhances tissue perfusion and tumour infiltration by immune cells, thereby improving the response to immunotherapy [100]. Additionally, preclinical evidence demonstrates that immunotherapy can improve the immunomodulatory effects of antiangiogenic therapy, as has been well illustrated in the available trial data [101]. Multiple clinical trials taking this into account have achieved the desired success. The combination of atezolizumab and bevacizumab (anti-VEGF) is intended to change the treatment landscape, as it is the first treatment to show superiority in front-line therapy for advanced HCC in recent years. It now appears to have an overwhelming advantage over the FDA-approved first-line options of sorafenib and lenvatinib [102]. Although specific VEGF/VEGFR inhibitors may enable antitumour immunity, multikinase inhibitors remain nonnegligible agents. Lenvatinib combined with pembrolizumab is another combination therapy for advanced HCC, and early data shows good prospects [103]. Lenvatinib plus AK104 (PD-1/CTLA-4 bispecific antibody) as a first-line therapy for unresectable HCC has shown promising antitumour activity and an acceptable safety profile [104]. This study was presented at the ASCO 2021 meeting and presents a few new ideas. Camerzumab (SHR-1210) in combination with apatinib has shown promising antitumour activity for HCC in a phase II study [105]. ICIs will probably become the backbone of systemic combination therapy for patients with HCC, but needs further study. The synergistic effects of ICIs and antiangiogenic drugs are being investigated in clinical trials (Table 2). This combination therapy represents an evolution of the present treatment options, which are supported by a powerful preclinical rationale.

Table 2 Ongoing trials investigating the combination therapy of TKIs and ICIs

Combination of immune checkpoint inhibitors

Because tumour escape mechanisms involve the aberrant expression of different immune checkpoint molecules, the combination of multiple ICIs for tumour treatment may result in enhanced efficacy (Table 3) [106]. The inhibition of PD-1/PD-L1 can activate prospective tumour immunity only if there are enough CD8+ T cells in the tumour tissue. Moreover, anti-CTLA-4 antibodies can increase the abundance of active CD8+ T cells by inhibiting the B7-CTLA-4 pathway and then promoting the infiltration of active CD8+ T cells into tumour tissue, thus enhancing the antitumour effect [107]. This principle provides the rationale for ongoing clinical trials of the simultaneous blockade of multiple immune checkpoints. The CheckMate 040 trial tested the effects of nivolumab plus ipilimumab in the second-line setting for advanced HCC patients [108]. Nivolumab in combination with ipilimumab had acceptable safety, an optimistic object response rate (ORR), and a durable response in that randomized trial. Another phase I/II trial to evaluate the efficacy and safety of durvalumab plus tremelimumab in unresectable HCC has also been reported [109]. The results of the experiment are exciting, and the next phase of the study should prove worthwhile. Finally, a promising direction of development is to establish more relevant preclinical models of HCC to identify the most potent combination strategies between anti-PD-1/PD-L1 antibodies and alternative immunomodulatory agents for further clinical development. There are various ongoing combination therapies of different ICIs in HCC (Table 3).

Table 3 Ongoing trials investigating the combination therapy of ICIs

Combination therapies are currently in diverse phases of clinical exploitation to optimize antitumour efficacy. The combination of locoregional therapy with immunotherapy and targeted therapy for advanced HCC plays a huge role in the clinic, particularly for advanced HCC [110, 111].

Currently approved treatment options

Systemic therapy has been recognized as a substantial benefit for patients with HCC. Table 4 summarizes the systemic therapeutic agents for HCC that are approved by the FDA.

Table 4 Systemic therapies approved for HCC by FDA

First-line therapy


Until 2017, sorafenib was the only potent treatment for patients who entered an advanced stage of HCC or failed other therapies. It is an oral MKI that blocks the activities of receptor tyrosine kinases (VEGFR-2/3, PDGFR-β, c-Kit, FLT-3, and RET), downstream pathway kinases (Ras/Raf/MAPK and JAK/STAT), and other targets (B-Raf and c- Raf) [112]. Sorafenib extends the mOS from 7.9 months to 10.7 months compared with the placebo arm [113]. The trial provides a standard study scheme for evaluating promising drugs. Similar benefits were identified in a parallel phase III trial in an Asian population, mostly with HBV-infected patients [114]. In later clinical trials, the OS of sorafenib-experienced patients appears to have increased; for example, the OS of patients in Asia increased from 6.5 months to 11 months and that of patients in the western region increased from 10.7 months to 15.1 months [115]. In these trials, the AEs were mostly similar and manageable, including hand-foot skin reactions, rash or desquamation, hypertension, diarrhoea, fatigue, and ascites.

The success of sorafenib to treat advanced HCC seems beneficial for earlier clinical stages, but it did not obtain the expected benefit in the placebo-controlled clinical trial [116, 117]. Although the widespread use of sorafenib increases the survival time of patients with HCC, its effective rate is low due to the formation of drug resistance [118]. Subsequently, several targeted drugs such as sunitinib, brivanib, erlotinib, linifanib, and lapatinib have been tested in a phase III trial over the past decade, but further breakthroughs were not made until the emergence of two other oral tyrosinase inhibitors: lenvatinib and regorafenib.


Lenvatinib is an oral MKI that blocks the behaviours of VEGFR1–3, FGFR1–4, PDGFR, RET, and KIT. In a phase III noninferiority randomized controlled trial involving 954 unresectable HCC patients worldwide, the role of lenvatinib was compared with sorafenib as a first-line therapy [119]. In this study, the mOS as the primary endpoint in the lenvatinib and sorafenib groups was 13.6 months and 12.3 months, respectively. With the tumour evaluation results conducted by mRECIST, lenvatinib had a statistically significant improvement in all secondary endpoints compared with sorafenib. Progression-free survival (PFS) and ORRs were significantly higher in the lenvatinib group (PFS: 7.4 months vs. 3.7 months; ORRs: 24.1% vs. 9.2%). Moreover, lenvatinib had greater survival benefits for HBV-related HCC patients [120]. Additionally, lenvatinib plays a promising role in delaying the deterioration of diseases, including role function, pain, and diarrhoea [121].

Notably, the treatment-related AEs were similar in patients receiving lenvatinib or sorafenib, although accompanied by a different incidence, predominantly of hypertension and thrombocytopenia. This may be because the median duration of the treatment was longer in the lenvatinib group than in the sorafenib group [119].

These trial results indicated that lenvatinib is not inferior to sorafenib as a first-line setting and is regarded as an optimal candidate for sorafenib. Consequently, lenvatinib as a first-line treatment was recently supported by the ESMO, EASL, and ASCO guidelines [122,123,124].

Atezolizumab plus bevacizumab

Recently, reliable data on the combination of atezolizumab and bevacizumab have been presented, and this therapeutic approach is approved by the FDA and is used in patients with unresectable or metastatic HCC who have not received prior systemic treatment [125]. The combination of angiogenesis inhibitors and PD-L1 inhibitors is designed to inhibit high levels of angiogenesis and overactivity of VEGF and PD-L1 in HCC tumours. In an initial study, atezolizumab plus bevacizumab was efficacious and clinically meaningful, and it had obvious clinical benefits compared with atezolizumab alone [126]. Furthermore, this combination therapy was compared with sorafenib in the phase III IMbrave150 trial. The OS rates at 12 months of the combination group and the sorafenib group were 67.2 and 54.6%, respectively. The combination treatment reduced the risk of death by 42% (HR: 0.58, P = 0.0006). The mPFS was 6.8 months and 4.3 months in the respective groups, and the risk of disease progression or death was reduced by 41% (HR: 0.59, P < 0.0001) [102]. OS and PFS, as the primary endpoints of the study, met the predefined statistical threshold. Atezolizumab plus bevacizumab compared with sorafenib delayed the deterioration of quality of life (time to deterioration: 11.2 months vs. 3.6 months, respectively). In addition, the grade 3–4 side effects of combination treatment were mainly hypertension and proteinuria, with no difference from those of atezolizumab and bevacizumab alone. In Chinese patients with advanced HCC, combination therapy has also resulted in substantial clinical improvements in OS and PFS [127].

Atezolizumab plus bevacizumab to treat HCC was first included in the ASCO guidelines in 2020 on the basis of the IMbrave150 trial [124].

Subsequent therapy

The efficacy of first-line agents in patients with HCC may be restricted by contraindications, drug resistance, and AEs, and it is necessary to replace first-line agents with sequential treatment in these situations.


Following the successful inclusion of regorafenib in the second-line setting, sequential therapy has been recognized as the standard modality. Regorafenib has profound antiproliferative and antiangiogenic effects on tumour cells by inhibiting VEGFR signal transduction, thereby regulating the tumour microenvironment. Its chemical structure differs from sorafenib only by a fluorine-carbon atom on the central benzene ring [128]. A randomized controlled phase III trial indicated mOS and mPFS improvement in further treatment of advanced HCC in sorafenib-experienced patients (mOS: 10.6 months vs 7.8 months; mPFS: 3.1 months vs 1.5 months). Meanwhile, the ORR, time to progression, and disease control rate (DCR) were also been increased. The AEs in the regorafenib group were similar to those in the sorafenib group, including high blood pressure, hand and foot skin reactions, fatigue, and diarrhoea [129]. Encouragingly, the study results of sorafenib-regorafenib sequential therapy demonstrated that from sorafenib treatment to death, the mOS was 26.0 months in the regorafenib group and 19.2 months in the placebo group [130]. There is evidence that the response rate to regorafenib is correlated with HCC molecular subtypes [131]. Therefore, regorafenib can bring significant survival benefits and can be used as an important choice for second-line therapy.


Cabozantinib is an oral MKI of VEGFR2, MET, AXL, KIT, and RET. In contrast to regorafenib, cabozantinib has been mainly developed as a second-line therapy for Child-Pugh A HCC. A phase 3 study of cabozantinib in the second-line setting for patients with advanced HCC showed improvement in OS, mPFS, and DCR compared with a placebo [132]. Cabozantinib increased the mPFS to 5.2 months from 1.9 months in the placebo group, and the risk of death in the cabozantinib group was reduced by 24%. The ORR was also significantly improved by 4.0% in the cabozantinib group and 0.4% in the placebo group. The majority of AEs were hand-foot syndrome, hypertension, fatigue, and transaminase elevation. The efficacy of cabozantinib is not completely consistent with the liver function of patients, but it shows a trend of a higher curative effect in patients with better liver function [133].


Briefly, ramucirumab is an anti-VEGFR2 mAb that directly targets the extracellular domain of VEGFR2 and prevents ligand-independent VEGFR2 signalling [134]. Compared with a placebo, ramucirumab did not greatly increase the survival time of unselected HCC patients [135]. However, ramucirumab increased the OS of advanced HCC patients with AFP > 400 ng/ml from 7.3 months to 8.5 months [136]. In addition, from 2015 to 2017, testing was conducted on 292 patients who still had tumour progression after receiving sorafenib. The primary inclusion criteria were impaired liver function, an AFP level of 400 ng/mL or greater, and resistance to sorafenib or progressive disease under sorafenib. The mOS and PFS were significantly increased in this specific group with approximately the same conclusions as previously [137]. Therefore, ramucirumab is a feasible second-line drug in advanced HCC patients with high AFP levels.


Nivolumab is the first anti-PD-1 antibody approved for the treatment of patients with HCC. In the CheckMate040 study, the manageable safety and durable efficacy of nivolumab treatment were indicated in ITT and Asian patients previously treated with sorafenib. The study results show an ORR of 20% and a DCR of 60%, and the efficacy is long lasting [138]. Unfortunately, as a first-line treatment for advanced HCC in CheckMate459, the primary endpoint of the nivolumab group (OS) was not statistically significant compared with sorafenib [68]. Following the results of the CheckMate040 study, nivolumab was conditionally granted approval by the FDA for the second-line treatment of HCC.


Pembrolizumab, another antibody against PD-1, is commonly considered a second-line treatment option for HCC. This decision is based on a nonrandomized KEYNOTE-224 study [81]. In this trial, a mOS of 12.9 months, a mPFS of 4.9 months, an ORR of 17%, and a DCR of 61% were recorded. The results of the subsequent randomized phase III trial have also been reported. The study results show that the preset statistically significant endpoint was not reached; however, the ORR of the pembrolizumab group was much higher than that of the placebo group (18.3% vs. 4.4%) [139]. Additionally, Asian people who received pembrolizumab had greater benefits with regard to OS, with an HR of 0.548 (95% CI 0.374, 0.804, P = 0.0009), and the survival benefit was better than that of patients in western regions [140].

Nivolumab plus ipilimumab

Recently, nivolumab plus ipilimumab was authorized by the FDA as a second-line treatment option for patients with advanced HCC who have received sorafenib. This novel treatment regimen achieved the combination blockade of the immune checkpoints PD-1 and CTLA-4, thereby improving the therapeutic effect for advanced HCC [141]. In the CheckMate-040 study, the efficacy and safety of the combination therapy with nivolumab and ipilimumab were assessed. This combination therapy appears to be safe and tolerable with a confirmed ORR of 33%. As another main efficacy outcome, the duration of response ranged from 4.6 months to 30.5+ months, with 31% of responses lasting at least 24 months. Moreover, combination therapy has shown common AEs similar to those seen with single-drug use. Subsequently, there have been additional clinical studies to evaluate the efficacy of combination immune checkpoint blockade for advanced HCC.

Challenges and future directions

There are several issues that need to be addressed soon with regard to the treatment of HCC (Fig. 3). Specifically, some biomarkers may be instructive for patient sensitivity to drugs and prognostic implications, such as AFP, which successfully influences treatment decisions in HCC [136]; no additional biomarkers have yet fulfilled this function. While extensive studies have been conducted to examine potential biomarkers to manage HCC [142,143,144,145], no available regimen has been developed to treat this tumour. This situation leads to the additional point that the optimal sequence strategy for these new agents is not yet clear. Therefore, it is critical to develop drug sensitivity biomarkers and prognostic biomarkers that identify patients who respond to appropriate treatments, to adopt a novel treatment strategy. Systematic and standardized collection and analysis of blood samples and tumour tissues from patients with HCC should be performed to further develop biomarker-based research.

Fig. 3
figure 3

Future directions in targeted therapy for HCC

In the clinic, drug resistance is also a major obstacle to systemic therapy for the treatment of HCC, particularly when newly developed drugs for HCC do not have remarkable results similar to those of other malignancies. The known mechanisms associated with resistance to targeted therapy include epigenetic biological processes, transport processes, regulated cell death, and the tumour microenvironment [146, 147]. Drug resistance, i.e., primary resistance and acquired resistance, is still the main reason for treatment failure during targeted therapy [148]. In addition, the AEs caused by the drugs themselves can have undesirable impacts on the health-related quality of life for patients, even leading to drug discontinuation [149]. These conditions can also be alleviated with combination and sequential therapies.

Finally, it is worth considering how to establish relevant preclinical models based on the heterogeneity of HCC and the tumour microenvironment and then integrate them with data collected from the human body.


Systemic treatment for patients with HCC is changing due to ever-improving molecular targeted therapies and immunotherapies. The evolution of targeted therapies provides rich data and promising results, particularly in patients who are not amenable to locoregional treatments.

The key success lies in tyrosine kinase inhibitors, which remarkably increase overall survival as a systemic therapy. There is hope for treating HCC at an early or intermediate stage with a better understanding of the molecular mechanisms of hepatocarcinogenesis or the discovery of potential biomarkers. Targeted and immune-based therapies will gradually become the standard treatment for HCC, offering a new strategy for advanced HCC treatment and management. Angiogenesis inhibitors and immune checkpoint inhibitors remain the mainstream approaches to treat HCC. Of these, the research results of several targeted agents in recent years have been successful.

Various clinical trials of systemic therapies are ongoing and have proven successful thus far. These trials are useful in determining the role and effect of molecular targeted therapies and immunotherapies, defining the optimal combinations, and assessing the optimal timing, i.e., adjuvant therapy and first-line or second-line therapy, and thus establishing rational treatment principles. Further exploration of targeted and immunotherapies in HCC is of great practical importance for controlling disease progression, improving the survival quality of patients, and guiding the rational use of clinical drugs.

Availability of data and materials

Not applicable.



adverse event


alpha fetoprotein


American Society of Clinical Oncology


Barcelona Clinic Liver Cancer


confidence interval.


cytokine-induced killer


disease control rate


epidermal growth factor


Food and Drug Administration


fibroblast growth factor


hepatitis B virus


hepatocellular carcinoma


hepatitis C virus


hazard ratio.


immune checkpoint inhibitors


insulin-like growth factor receptor


Janus kinase/signal transducer activator of transcription factor pathway


lymphocyte activation gene-3


monoclonal antibodies


median overall survival


median progression-free survival


noncoding RNA


multikinase inhibitor


not available


not evaluated


object response rate


overall survival


platelet-derived growth factor


programmed death-1


programmed death ligand-1


progression-free survival


phosphoinositide 3-kinase–AKT–mammalian target of rapamycin pathway


partial response


phosphate and tension homology deleted on chromosome ten


mitogen-activated protein kinase pathway


response evaluation criteria in solid tumours


relapse-free survival.


transforming growth factor-β


T cell Ig and immunoreceptor tyrosine-based inhibitory motif domain


T cell immunoglobulin and mucin-containing protein 3


tyrosine kinase inhibitor


time to progression


vascular endothelial growth factor


V-domain Ig suppressor of T cell activation.


  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  PubMed  Google Scholar 

  2. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450–62.

    Article  CAS  PubMed  Google Scholar 

  3. Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, van Poucke S, et al. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol. 2017;66(2):412–23.

    Article  PubMed  Google Scholar 

  4. Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477–491.e1.

    Article  PubMed  Google Scholar 

  5. Deng G-L, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: new advances and challenges. World J Hepatol. 2015;7:787–98.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kudo M. Management of Hepatocellular Carcinoma in Japan as a world-leading model. Liver Cancer. 2018;7(2):134–47.

    Article  PubMed  Google Scholar 

  7. Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37:543–50.

    Article  CAS  PubMed  Google Scholar 

  8. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in Cancer. Front Oncol. 2014;4:64.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat signaling induced by Interleukin-6 family cytokines in hepatocellular carcinoma. Cancers (Basel). 2019;11(11):1704.

  10. Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers (Basel). 2020;12(2).

  11. Dhanasekaran R, Nault J-C, Roberts LR, Zucman-Rossi J. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy. Gastroenterology. 2019;156:492–509.

    Article  CAS  PubMed  Google Scholar 

  12. Cheng H, Sun G, Chen H, Li Y, Han Z, Li Y, et al. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. Am J Cancer Res. 2019;9:1536–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Abd El Aziz MA, Facciorusso a, Nayfeh T, Saadi S, Elnaggar M, Cotsoglou C, Sacco R. Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines (Basel) 2020;8(4):616. .

  14. Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48:598–609.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Huang A, Yang X-R, Chung W-Y, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5:146.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681–700.

    Article  CAS  PubMed  Google Scholar 

  17. Vogel A, Saborowski A. Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer Treat Rev. 2020;82:101946.

    Article  CAS  PubMed  Google Scholar 

  18. Chen S, Cao Q, Wen W, Wang H. Targeted therapy for hepatocellular carcinoma: challenges and opportunities. Cancer Lett. 2019;460:1–9.

    Article  CAS  PubMed  Google Scholar 

  19. Chen C, Wang G. Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol. 2015;7:1964–70.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1.

  21. Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13(1):113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Huynh H, Nguyen TTT, Chow K-HP, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M, et al. Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int. 2004;24:432–6.

    Article  CAS  PubMed  Google Scholar 

  24. Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS, et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res. 2004;29:113–21.

    Article  CAS  PubMed  Google Scholar 

  25. Min L, He B, Hui L. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol. 2011;21:10–20.

    Article  CAS  PubMed  Google Scholar 

  26. Chen L, Shi Y, Jiang C-Y, Wei L-X, Wang Y-L, Dai G-H. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. Eur J Surg Oncol. 2011;37:513–20.

    Article  CAS  PubMed  Google Scholar 

  27. Zhou X, Zhu A, Gu X, Xie G. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation. Cell Oncol (Dordr). 2019;42:369–80.

    Article  CAS  Google Scholar 

  28. Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, et al. Phase II studies with Refametinib or Refametinib plus Sorafenib in patients with RAS-mutated hepatocellular carcinoma. Clin Cancer Res. 2018;24:4650–61.

    Article  CAS  PubMed  Google Scholar 

  29. Kim R, Tan E, Wang E, Mahipal A, Chen D-T, Cao B, et al. A phase I trial of Trametinib in combination with Sorafenib in patients with advanced hepatocellular Cancer. Oncologist. 2020;25(12):e1893-1899.

  30. Chung T-W, Lee Y-C, Kim C-H. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J. 2004;18:1123–5.

    Article  CAS  PubMed  Google Scholar 

  31. Erhardt A, Hassan M, Heintges T, Häussinger D. Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-off cell line. Virology. 2002;292:272–84.

    Article  CAS  PubMed  Google Scholar 

  32. Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18:744–57.

    Article  CAS  PubMed  Google Scholar 

  33. Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, de LMM. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci. 2020;21(4):1266.

  34. Khalid A, Hussain T, Manzoor S, Saalim M, Khaliq S. PTEN: a potential prognostic marker in virus-induced hepatocellular carcinoma. Tumour Biol. 2017;39:1010428317705754.

    Article  CAS  PubMed  Google Scholar 

  35. Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol. 2013;60:855–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 2010;27:255–61.

    Article  CAS  PubMed  Google Scholar 

  37. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004;10(24):8421–5.

    Article  CAS  PubMed  Google Scholar 

  38. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142:1021–1031.e15.

    Article  CAS  PubMed  Google Scholar 

  39. Lu X, Paliogiannis P, Calvisi DF, Chen X. Role of the mammalian target of rapamycin pathway in liver Cancer: from molecular genetics to targeted therapies. Hepatology. 2021;73(Suppl 1):49–61.

    Article  CAS  PubMed  Google Scholar 

  40. Yang S, Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett. 2017;13(3):1041–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Han T, Xiang D-M, Sun W, Liu N, Sun H-L, Wen W, et al. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. J Hepatol. 2015;63:651–60.

    Article  CAS  PubMed  Google Scholar 

  42. Zhu Y-J, Zheng B, Wang H-Y, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38(5):614–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, et al. mTOR inhibition is Most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg. 2020;272(5):855–62.

    Article  PubMed  Google Scholar 

  44. Perugorria MJ, Olaizola P, Labiano I, Esparza-Baquer A, Marzioni M, Marin JJG, et al. Wnt-β-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16:121–36.

    Article  CAS  PubMed  Google Scholar 

  45. Cui Y, Wu X, Lin C, Zhang X, Ye L, Ren L, et al. AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/β-catenin/CBP signaling pathway. Oncogene. 2019;38:5516–29.

    Article  CAS  PubMed  Google Scholar 

  46. Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol. 2016;22:823–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma. 2018;5:61–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.

    Article  PubMed  Google Scholar 

  49. Hu Z, Wang P, Lin J, Zheng X, Yang F, Zhang G, et al. MicroRNA-197 promotes metastasis of hepatocellular carcinoma by activating Wnt/β-catenin signaling. Cell Physiol Biochem. 2018;51:470–86.

    Article  CAS  PubMed  Google Scholar 

  50. Srisuttee R, Koh SS, Kim SJ, Malilas W, Boonying W, Cho I-R, et al. Hepatitis B virus X (HBX) protein upregulates β-catenin in a human hepatic cell line by sequestering SIRT1 deacetylase. Oncol Rep. 2012;28:276–82.

    Article  CAS  PubMed  Google Scholar 

  51. Wang W, Pan Q, Fuhler GM, Smits R, Peppelenbosch MP. Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J Gastroenterol. 2017;52:419–31.

    Article  CAS  PubMed  Google Scholar 

  52. Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23:1422–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK/STAT signaling in hepatocellular carcinoma. Hepat Oncol. 2020;7:HEP18.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Yang S, Luo C, Gu Q, Xu Q, Wang G, Sun H, et al. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. Oncotarget. 2016;7:5461–9.

    Article  PubMed  Google Scholar 

  55. Wang X, Liao X, Yu T, Gong Y, Zhang L, Huang J, et al. Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma. Int J Oncol. 2019;55:805–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Maugeri-Saccà M, de Maria R. The hippo pathway in normal development and cancer. Pharmacol Ther. 2018;186:60–72.

    Article  CAS  PubMed  Google Scholar 

  57. Calses PC, Crawford JJ, Lill JR, Dey A. Hippo pathway in Cancer: aberrant regulation and therapeutic opportunities. Trends Cancer. 2019;5:297–307.

    Article  CAS  PubMed  Google Scholar 

  58. Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61(5):1088–96.

    Article  CAS  PubMed  Google Scholar 

  59. Zhang S, Zhou D. Role of the transcriptional coactivators YAP/TAZ in liver cancer. Curr Opin Cell Biol. 2019;61:64–71.

    Article  CAS  PubMed  Google Scholar 

  60. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Reis H, Bertram S, Pott L, Canbay A, Gallinat A, Baba HA. Markers of hippo-pathway activity in tumor forming liver lesions. Pathol Oncol Res. 2017;23:33–9.

    Article  CAS  PubMed  Google Scholar 

  62. Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019;25:912–20.

    Article  CAS  PubMed  Google Scholar 

  63. Zhang L, Wang J-N, Tang J-M, Kong X, Yang J-Y, Zheng F, et al. VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Mol Biol Rep. 2012;39:5085–93.

    Article  CAS  PubMed  Google Scholar 

  64. Dai S, Zhou Z, Chen Z, Xu G, Chen Y. Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors. Cells. 2019;8(6):614.

  65. Demoulin J-B, Essaghir A. PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev. 2014;25:273–83.

    Article  CAS  PubMed  Google Scholar 

  66. Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17:58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  CAS  PubMed  Google Scholar 

  68. Yau T, Park JW, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v874–5.

    Article  Google Scholar 

  69. Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12:27.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol. 2019;25:3136–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Bangaru S, Marrero JA, Singal AG. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51(1):78–89.

    Article  CAS  PubMed  Google Scholar 

  72. Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De RV, Facchini G, et al. Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol. 2016;7:428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Huang S-Z, Wei M-N, Huang J-R, Zhang Z-J, Zhang W-J, Jiang Q-W, et al. Targeting TF-AKT/ERK-EGFR pathway suppresses the growth of hepatocellular carcinoma. Front Oncol. 2019;9:150.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Lim HY, Heo J, Choi HJ, Lin C-Y, Yoon J-H, Hsu C, et al. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):5976–85.

    Article  CAS  PubMed  Google Scholar 

  75. Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, et al. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol. 2016;27:2210–5.

    Article  CAS  PubMed  Google Scholar 

  76. Zhang J, Zong Y, Xu G-Z, Xing K. Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. Saudi Med J. 2016;37:1184–90.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Lett. 2020;470:8–17.

    Article  CAS  PubMed  Google Scholar 

  78. Cheng H-Y, Kang P-J, Chuang Y-H, Wang Y-H, Jan M-C, Wu C-F, et al. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. PLoS One. 2014;9:e95870.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–52.

    Article  PubMed  Google Scholar 

  82. Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21:571–80.

    Article  CAS  PubMed  Google Scholar 

  83. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599–616.

    Article  PubMed  Google Scholar 

  84. Sangro B, Gomez-Martin C, La Mata M de, Iñarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81–88. doi:

  85. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.

    Article  CAS  PubMed  Google Scholar 

  86. Matsui HM, Hazama S, Nakajima M, Xu M, Matsukuma S, Tokumitsu Y, et al. Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial. Cancer Immunol Immunother. 2020;70(4):945–57.

    Article  CAS  PubMed  Google Scholar 

  87. Rochigneux P, Chanez B, de Rauglaudre B, Mitry E, Chabannon C, Gilabert M. Adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase Clinical trials. Cancers (Basel). 2021.

  88. Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, et al. Chimeric antigen receptor-Glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26:3979–89.

    Article  CAS  PubMed  Google Scholar 

  89. Zhao Z, Guo W, Fang S, Song S, Song J, Teng F, et al. An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: a phase I trial. JCO. 2021;39:4095.

    Article  Google Scholar 

  90. Li J, Xing J, Yang Y, Liu J, Wang W, Xia Y, et al. Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2020;5:548–60.

    Article  PubMed  Google Scholar 

  91. Kaseb A, Duda DG, Tran Cao HS, Abugabal YI, Vence LM, Rashid A, et al. Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. Ann Oncol. 2019;30:v880.

    Article  Google Scholar 

  92. Pinato DJ, Cortellini A, Pai M, Spalding D, Talbot T, Goldin RD, et al. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. JCO. 2021;39(15_suppl):e16131.

    Article  Google Scholar 

  93. Lee JH, Lee J-H, Lim Y-S, Yeon JE, Song T-J, Yu SJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148:1383–91.e6.

    Article  CAS  PubMed  Google Scholar 

  94. Yu SJ, Ma C, Heinrich B, Brown ZJ, Sandhu M, Zhang Q, et al. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. J Hepatol. 2019;70:449–57.

    Article  CAS  PubMed  Google Scholar 

  95. Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21(37):10584–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Wilson CL, Mann DA, Borthwick LA. Epigenetic reprogramming in liver fibrosis and cancer. Adv Drug Deliv Rev. 2017;121:124–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Bayo J, Fiore EJ, Dominguez LM, Real A, Malvicini M, Rizzo M, et al. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets. J Hepatol. 2019;71(1):78–90.

    Article  CAS  PubMed  Google Scholar 

  98. Khan FS, Ali I, Afridi UK, Ishtiaq M, Mehmood R. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics. Hepatol Int. 2017;11(1):45–53.

    Article  PubMed  Google Scholar 

  99. Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MI. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103–19.

    Article  CAS  PubMed  Google Scholar 

  100. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Raybould AL, Sanoff H. Combination antiangiogenic and immunotherapy for advanced hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma. 2020;7:133–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894–905.

    Article  CAS  PubMed  Google Scholar 

  103. Zhu AX, Finn RS, Ikeda M, Sung MW, Baron AD, Kudo M, et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). JCO. 2020;38:4519.

    Article  Google Scholar 

  104. Bai L, Sun M, Xu A, Bai Y, Wu J, Shao G, et al. Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma. JCO. 2021;39:4101.

    Article  Google Scholar 

  105. Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, et al. Camrelizumab in combination with Apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, Phase II Trial. Clin Cancer Res. 2021;27:1003–11.

    Article  CAS  PubMed  Google Scholar 

  106. Cheng A-L, Hsu C, Chan SL, Choo S-P, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72(2):307–19.

    Article  CAS  PubMed  Google Scholar 

  107. Kudo M. Combination Cancer immunotherapy in hepatocellular carcinoma. Liver Cancer. 2018;7:20–7.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of Nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib: the CheckMate 040 randomized Clinical trial. JAMA Oncol. 2020;6(11):e204564.

  109. Kelley RK, Abou-Alfa GK, Bendell JC, Kim T-Y, Borad MJ, Yong W-P, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. JCO. 2017;35(15_suppl):4073.

    Article  Google Scholar 

  110. Dendy MS, Ludwig JM, Stein SM, Kim HS. Locoregional therapy, immunotherapy and the combination in hepatocellular carcinoma: future directions. Liver Cancer. 2019;8:326–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Meng M, Li W, Yang X, Huang G, Wei Z, Ni Y, Han X, Wang J, Ye X Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): a novel treatment for patients with advanced hepatocellular carcinoma. J Cancer Res Ther 2020;16:327–334. doi:10.4103/jcrt.JCRT_101_20, 2.

  112. Li Y, Gao Z-H, Qu X-J. The adverse effects of sorafenib in patients with advanced cancers. Basic Clin Pharmacol Toxicol. 2015;116:216–21.

    Article  CAS  PubMed  Google Scholar 

  113. Harnois D. Sorafenib in advanced hepatocellular carcinoma. Yearbook Gastroenterology. 2009;2009:218–9.

    Article  Google Scholar 

  114. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

    Article  CAS  PubMed  Google Scholar 

  115. Cheng A-L, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2017;35:4001.

    Article  Google Scholar 

  116. Meyer T, Fox R, Yt M. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial (vol 2, pg 565, 2017). Lancet Gastroenterol Hepatol. 2017;2:E6.

    Article  Google Scholar 

  117. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64:1090–8.

    Article  CAS  PubMed  Google Scholar 

  118. Méndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50(10):1–9.

    Article  CAS  PubMed  Google Scholar 

  119. Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

    Article  CAS  PubMed  Google Scholar 

  120. Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Cheng A-L, et al. Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). J Clin Oncol. 2019;37:186.

    Article  Google Scholar 

  121. Vogel A, Qin S, Kudo M, Hudgens S, Yamashita T, Yoon J-H, et al. Health-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Ann Oncol. 2017;28:v210.

    Article  Google Scholar 

  122. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238–55.

    Article  CAS  PubMed  Google Scholar 

  123. EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.

    Article  Google Scholar 

  124. John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Muhammad Shaalan beg, Steven T. Brower, Terence P. Gade, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.

  125. US FDA. FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.,not%20received%20prior%20systemic%20therapy. .

  126. Lee MS, Ryoo B-Y, Hsu C-H, Numata K, Stein S, Verret W, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808–20.

    Article  CAS  PubMed  Google Scholar 

  127. Qin S, Galle PR, ZhenggangRen Y-HF, Yau T, Wang B, et al. Efficacy and safety of atezolizumab + bevacizumab vs sorafenib in Chinese patients with unresectable HCC in the phase III IMbrave150 study. Liver Cancer Summit. 2020;abstract:OP02–3.

    Google Scholar 

  128. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–55.

    Article  CAS  PubMed  Google Scholar 

  129. Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.

    Article  CAS  PubMed  Google Scholar 

  130. Finn RS, Merle P, Granito A, Huang Y-H, Bodoky G, Pracht M, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. J Hepatol. 2018;69(2):353–8.

    Article  CAS  PubMed  Google Scholar 

  131. Hoshida Y, Nijman SMB, Kobayashi M, Chan JA, Brunet J-P, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69:7385–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Abou-Alfa GK, Meyer T, Cheng A-L, El-Khoueiry AB, Rimassa L, Ryoo B-Y, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Miksad R, Cicin I, Chen Y, Klumpen H, Kim S, Lin Z, et al. Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ann Oncol. 2019;30:iv134.

    Article  Google Scholar 

  134. Syed YY. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs. 2020;80:315–22.

    Article  CAS  PubMed  Google Scholar 

  135. Zhu AX, Park JO, Ryoo B-Y, Yen C-J, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. 2015;16(7):859–70.

    Article  CAS  PubMed  Google Scholar 

  136. Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. JCO. 2018;36(15_suppl):4003.

    Article  Google Scholar 

  137. Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–96.

    Article  CAS  PubMed  Google Scholar 

  138. Yau T, Hsu C, Kim T-Y, Choo S-P, Kang Y-K, Hou M-M, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 2019;71:543–52.

    Article  CAS  PubMed  Google Scholar 

  139. Finn RS, Ryoo B-Y, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193–202.

    Article  CAS  PubMed  Google Scholar 

  140. Kudo M, Lim HY, Cheng A-L, Chao Y, Yau T, Ogasawara S, et al. Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup. JCO. 2020;38(4_suppl):526.

    Article  Google Scholar 

  141. Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of Nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib: the CheckMate 040 randomized Clinical trial. JAMA Oncol. 2020;6:e204564.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, et al. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J Hepatol. 2018;69:826–39.

    Article  CAS  PubMed  Google Scholar 

  143. Cao L, Cheng H, Jiang Q, Li H, Wu Z. APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Aging (Albany NY). 2020;12:4573–91.

    Article  CAS  Google Scholar 

  144. Gu Y, Li X, Bi Y, Zheng Y, Wang J, Li X, et al. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY). 2020;12:784–807.

    Article  CAS  Google Scholar 

  145. Huang B, Tian Z-F, Li L-F, Fan Y, Yin H-Y, Li Y, et al. LHX3 is an advanced-stage prognostic biomarker and metastatic oncogene in hepatocellular carcinoma. Cancer Biomark. 2019;26(1):31–9.

    Article  CAS  PubMed  Google Scholar 

  146. Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.

    Article  PubMed  PubMed Central  Google Scholar 

  147. Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020;51:102610.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG. New insights into sorafenib resistance in hepatocellular carcinoma: responsible mechanisms and promising strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2017;1868(2):564–70.

    Article  CAS  Google Scholar 

  149. Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019;77:20–8.

    Article  CAS  PubMed  Google Scholar 

Download references


Not applicable.


This study was supported by grants from the National Natural Science Foundation of China (Nos. 81872255 and 62041101) and the Key Medical Talents Foundation of Jiangsu Province (2016KJQWZDRC-03).

Author information

Authors and Affiliations



All authors made substantial and intellectual contributions to the review. Under the direction of the corresponding author, Xin Qing and Wenjing Xu,organized and wrote this review, and Jingjing Zong, Xuanlong Du, and Hao Peng commented on this manuscript. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Yewei Zhang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors consent to publication.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qing, X., Xu, W., Zong, J. et al. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 9, 64 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: